Table 1.
Characteristics of the Participants (N = 170)
| Time from surgery to enrollment, y | |
| Median (Q1-Q3) | 3.0 (2.1-3.9) |
| Mean ± SD | 3.1 ± 1.2 |
| Age, y | |
| Median (Q1-Q3) | 59 (51-65) |
| Mean ± SD | 59 ± 10 |
| BMI, kg/m2 | |
| Median (Q1-Q3) | 29.0 (25.5-33.5) |
| Mean ± SD | 29.8 ± 5.5 |
| Left ventricular ejection fraction, % | |
| Median (Q1-Q3) | 62.8 (59.4-65.1) |
| Mean ± SD | 62.1 ± 4.5 |
| Not available | 21 |
| Race | |
| Non-Hispanic White | 105 (62) |
| Other group | 65 (38) |
| Smoking | |
| Never | 106 (63) |
| Former | 55 (33) |
| Current | 7 (4.2) |
| Unknown | 2 (1.2) |
| Disease stage | |
| I | 96 (57) |
| II | 59 (35) |
| III | 14 (8) |
| Unknown | 1 (<1) |
| Clinical subtype | |
| ER+/PR+/HER2− | 101 (60) |
| HER2+ | 34 (20) |
| ER−/PR−/HER2− | 28 (17) |
| Other | 6 (3) |
| Unknown | 1 (<1) |
| Surgery | |
| Lumpectomy | 86 (51) |
| Mastectomy | 84 (49) |
| Previous chemotherapy | 99 (58) |
| Previous radiotherapy | 121 (71) |
| Current endocrine therapy | 123 (72) |
| Current medications | |
| Beta-blockers | 24 (14) |
| ACE inhibitors | 30 (18) |
| Angiotensin receptor blockers | 12 (7.1) |
| Diuretic | 33 (19) |
| Aspirin/antiplatelet | 34 (20) |
| Statins | 39 (23) |
| Calcium-channel blocker | 14 (8.2) |
| Pre-existing (controlled) cardiovascular conditions | |
| Coronary artery disease | 3 (1.8) |
| Osteoporosis | 13 (7.6) |
| Arthritis | 22 (13) |
| Type II diabetes | 18 (11) |
| Hyperlipidemia | 41 (24) |
| Hypertension | 68 (40) |
| Any | 93 (55) |
Values are n or n (%) unless otherwise indicated.
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; BMI = body mass index; ER = estrogen receptor; HER2 = human epidermal growth factor; PR = progesterone receptor.